The U.S. Food and Drug Administration on Tuesday approved Pfizer's RSV vaccine for the prevention of lower respiratory tract disease caused by RSV in adults aged 18 to 59 at increased risk of the disease.

“These promising data add to the evidence supporting GSK’s RSV vaccine and could help expand protection to more adults at risk from RSV disease,” the company’s chief scientific officer, Tony Wood, Ph.D., said in a release. “They also provide valuable insights into the potential impact of a second dose for certain populations.”

A new FDA approval has given Pfizer a broader label for its respiratory syncytial virus (RSV) vaccine Abrysvo than rival shots from GSK and Moderna, but it may not make much of a difference in the battle for market share.

Abrysvo is now approved to prevent lower respiratory tract disease caused by RSV in high-risk adults aged over 18 years.

While it’s a win for Pfizer over GSK and its RSV vaccine Arexvy, which is approved for those 50 and older, it’s difficult to determine how much advantage will be gained from the nod as the Centers for Disease Control (CDC) will have to sign off on Abvrysvo's use in the wider age group.

Abrysvo can prevent lower respiratory tract disease caused by RSV for people between the ages of 18 and 59 who are at increased risk. It is the first RSV vaccine indicated for adults younger than 50,

Approval of Pfizer's Abrysvo in certain adults aged 18 to 59 years old will expand the number of people eligible for vaccination with the shot.

On Tuesday, the US Food and Drug Administration approved Pfizer’s respiratory syncytial virus (RSV) vaccine, Abrysvo, for people 18 to 59 who are more vulnerable to the virus.

The CDC’s vaccine advisors on Thursday maintained that respiratory syncytial virus immunization is only recommended for adults aged 75 and older, and in seniors 60 to 74 years who are at risk of severe disease.

Abrysvo is the first vaccine for the respiratory syncytial virus that is indicated for adults younger than 50, the drugmaker said.

Pfizer Inc. PFE announced that the FDA has granted approval for the expanded use of its respiratory syncytial virus (RSV) vaccine, Abrysvo, in adults aged 18-59 years. The vaccine has been approved for the prevention of lower respiratory tract disease (LRTD) caused by RSV in patients aged 18-59 years who are at increased risk of the disease.